News for October 2015

News Archive

New Study from TSRI and Salk Points to Cause of Debilitating Nerve Disease New Study from TSRI and Salk Points to Cause of Debilitating Nerve Disease

Findings Could Lead to Treatments for Charcot-Marie-Tooth Disease

Glimmer of hope for Duchenne muscular dystrophy Glimmer of hope for Duchenne muscular dystrophy

Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.

National Biologics Manufacturing Centre Launched

The Centre for Process Innovation (CPI) has officially launched the new £38m National Biologics Manufacturing Centre in Darlington, Co. Durham. The new Centre was opened by Jo Johnson, Minister of State for Universities and Science and Steve Bagshaw, CEO of Fujifilm Diosynth Biotechnologies. The new Centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.

Breast Cancer Drug Beats Superbug Breast Cancer Drug Beats Superbug

Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies

Cancer Research UK Launches £100m Grand Challenges to Tackle the Most Important Questions in Cancer Cancer Research UK Launches £100m Grand Challenges to Tackle the Most Important Questions in Cancer

CANCER RESEARCH UK has today (Monday) launched Grand Challenges* - the biggest and most ambitious cancer grants in the world - which aim to overcome the greatest barriers standing in the way of beating cancer.

New publication highlights A1M protein’s role in regulating free haemoglobin New publication highlights A1M protein’s role in regulating free haemoglobin

Scientists associated with A1M Pharma have published a scientific article that deepens the understanding of how free hemoglobin affects the function of the heart and the possibility to neutralize these effects with A1M, a protein that occurs naturally in the human body. The article was published on September 25 in the scientific journal Free Radical Biology and Medicine.

30 years on CANTAB inventors herald the dawn of a new era in neuroscience 30 years on CANTAB inventors herald the dawn of a new era in neuroscience

Three decades ago two emerging neuroscientists, Barbara Sahakian and Trevor Robbins from University of Cambridge received a grant from The Wellcome Trust to fund their development of the Cambridge Neuropsychological Automated Test Battery or CANTAB™. Delegates to CANTAB 30, a special conference held recently at the University of Cambridge to mark 30 years of expert cognitive neuroscience, heard how CANTAB™, has fundamentally changed the way brain function is measured and understood, leading to the dawn of a new era in neuroscience.

Cambridge Cognition enters ‘Hot’ Cognition arena Cambridge Cognition enters ‘Hot’ Cognition arena

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces two new licence agreements which extend the Company’s testing capabilities into new areas of research, enabling assessment of 'Hot' cognition – mental processes that are influenced by emotion and social interaction – to be performed reliably and routinely for the first time.

Social scientists needed to solve the problem of antibiotic overuse Social scientists needed to solve the problem of antibiotic overuse

overuse“The rise of resistance to antibiotics (Anti-Microbial Resistance, AMR) is largely a consequence of human action, and is as much a societal problem as a technological one.”

Patent filings research reveals the true potential of 3D printing technology in medical science, says Withers & Rogers Patent filings research reveals the true potential of 3D printing technology in medical science, says Withers & Rogers

According to patent filing research conducted by intellectual property firm Withers & Rogers, the 3D printing of medical devices and prosthetics is set to become common practice over the next 10 years. Due to the commercial limitations however, we’re unlikely to see 3D-printed drugs manufactured on such a wide basis.